KR20230169172A - 질량 분광법에 의한 인슐린-유사 성장 인자-i 변이체의 식별화 및 정량화 - Google Patents
질량 분광법에 의한 인슐린-유사 성장 인자-i 변이체의 식별화 및 정량화 Download PDFInfo
- Publication number
- KR20230169172A KR20230169172A KR1020237035826A KR20237035826A KR20230169172A KR 20230169172 A KR20230169172 A KR 20230169172A KR 1020237035826 A KR1020237035826 A KR 1020237035826A KR 20237035826 A KR20237035826 A KR 20237035826A KR 20230169172 A KR20230169172 A KR 20230169172A
- Authority
- KR
- South Korea
- Prior art keywords
- igf
- sample
- variants
- mass
- ions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 194
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title claims abstract description 125
- 238000004949 mass spectrometry Methods 0.000 title claims description 53
- 238000011002 quantification Methods 0.000 title description 33
- 150000002500 ions Chemical class 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 95
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims abstract description 73
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims abstract description 13
- 210000002966 serum Anatomy 0.000 claims description 45
- 238000001514 detection method Methods 0.000 claims description 40
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 102220289911 rs963277918 Human genes 0.000 claims description 13
- 102220630834 Interferon alpha-8_P66A_mutation Human genes 0.000 claims description 6
- 102220624353 Interferon alpha-8_P66T_mutation Human genes 0.000 claims description 6
- 102200027637 rs121909723 Human genes 0.000 claims description 6
- 102220516107 Exostosin-1_M59R_mutation Human genes 0.000 claims description 5
- 102220522628 Urotensin-2 receptor_A70P_mutation Human genes 0.000 claims description 5
- 102220518444 Enhancer of filamentation 1_T29I_mutation Human genes 0.000 claims description 4
- 102200058925 rs121909538 Human genes 0.000 claims description 4
- 102220041372 rs34084741 Human genes 0.000 claims description 4
- 102200098660 rs200754249 Human genes 0.000 claims 2
- 102220187197 rs3809694 Human genes 0.000 claims 2
- 239000000523 sample Substances 0.000 description 93
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 81
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 78
- 230000000155 isotopic effect Effects 0.000 description 57
- 239000012491 analyte Substances 0.000 description 42
- 238000003556 assay Methods 0.000 description 28
- 238000004811 liquid chromatography Methods 0.000 description 26
- 238000011084 recovery Methods 0.000 description 25
- 102220595155 GDNF-inducible zinc finger protein 1_A70T_mutation Human genes 0.000 description 20
- 239000013610 patient sample Substances 0.000 description 19
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 18
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 18
- 102200077239 rs5030980 Human genes 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000000605 extraction Methods 0.000 description 17
- 239000012071 phase Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 238000004896 high resolution mass spectrometry Methods 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000004885 tandem mass spectrometry Methods 0.000 description 14
- 238000001712 DNA sequencing Methods 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 230000000717 retained effect Effects 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000000132 electrospray ionisation Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 238000003908 quality control method Methods 0.000 description 10
- 102200012541 rs111033647 Human genes 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010018910 Haemolysis Diseases 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000008588 hemolysis Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 206010023126 Jaundice Diseases 0.000 description 8
- 150000001793 charged compounds Chemical class 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102220595163 GDNF-inducible zinc finger protein 1_A67S_mutation Human genes 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 102000044162 human IGF1 Human genes 0.000 description 7
- 230000006920 protein precipitation Effects 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- 102220198145 rs1057519886 Human genes 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 240000007241 Agrostis stolonifera Species 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000007385 chemical modification Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 102220290057 rs536755693 Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 4
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 4
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 4
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 4
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 4
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 4
- 101000599952 Mus musculus Insulin-like growth factor I Proteins 0.000 description 4
- 102220471540 Single-stranded DNA cytosine deaminase_Y31H_mutation Human genes 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 102220358488 c.167G>A Human genes 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005040 ion trap Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102200027638 rs121909721 Human genes 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 238000012935 Averaging Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102200113085 rs113831133 Human genes 0.000 description 3
- 102220278226 rs1554096641 Human genes 0.000 description 3
- 102220056956 rs730880943 Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000004770 highest occupied molecular orbital Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- LQERIDTXQFOHKA-UHFFFAOYSA-N nonadecane Chemical compound CCCCCCCCCCCCCCCCCCC LQERIDTXQFOHKA-UHFFFAOYSA-N 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000012950 reanalysis Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 102200044889 rs121913413 Human genes 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000002098 selective ion monitoring Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002553 single reaction monitoring Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000006302 Laron syndrome Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 101001076293 Mus musculus Insulin-like growth factor II Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013079 data visualisation Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163502P | 2021-03-19 | 2021-03-19 | |
| US63/163,502 | 2021-03-19 | ||
| PCT/US2022/020906 WO2022198020A1 (en) | 2021-03-19 | 2022-03-18 | Identification and quantitation of insulin-like growth factor-i variants by mass spectrometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230169172A true KR20230169172A (ko) | 2023-12-15 |
Family
ID=83284520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237035826A Pending KR20230169172A (ko) | 2021-03-19 | 2022-03-18 | 질량 분광법에 의한 인슐린-유사 성장 인자-i 변이체의 식별화 및 정량화 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12222354B2 (enExample) |
| EP (1) | EP4308923A4 (enExample) |
| JP (1) | JP2024515443A (enExample) |
| KR (1) | KR20230169172A (enExample) |
| CN (1) | CN117178188A (enExample) |
| CA (1) | CA3212218A1 (enExample) |
| WO (1) | WO2022198020A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117589998B (zh) * | 2023-10-09 | 2025-11-18 | 融智生物科技（青岛）有限公司 | 胰岛素样生长因子i变体的定量检测试剂盒 |
| CN117589997B (zh) * | 2023-10-09 | 2025-11-21 | 融智生物科技（青岛）有限公司 | Igf-1变体的定量检测方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080064044A9 (en) | 1995-05-23 | 2008-03-13 | Nelson Randall W | Analysis of insulin-like growth factors from biological fluids by the use of affinity-based mass spectrometric methods |
| US20030027216A1 (en) * | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
| WO2005101017A1 (en) * | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| EP1791551B1 (en) | 2004-08-30 | 2020-02-26 | Ipsen Biopharmaceuticals, Inc. | Method and device for diagnosing and treating insulin-like growth factor deficiency disorders |
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| ES2453108T3 (es) | 2007-08-06 | 2014-04-04 | Orion Genomics, Llc | Nuevos polimorfismos de un único nucleótido y combinaciones de polimorfismos nuevos y conocidos para determinar la expresión específica de alelo del gen IGF2 |
| EP2396429B1 (en) | 2009-02-11 | 2015-05-27 | Orion Genomics, LLC | Combinations of polymorphisms for determining allele-specific expression of igf2 |
| EP3095457B1 (en) | 2009-11-05 | 2018-05-16 | Quest Diagnostics Investments Incorporated | Quantitation of insulin-like growth factor-i with high-resolution mass spectrometry |
| WO2015106224A2 (en) * | 2014-01-12 | 2015-07-16 | Hugh Mctavish | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| CN109957000B (zh) * | 2017-12-14 | 2022-08-02 | 南开大学 | 一种促进细胞增殖的多肽衍生物及其制备方法及应用 |
-
2022
- 2022-03-17 US US17/697,813 patent/US12222354B2/en active Active
- 2022-03-18 JP JP2023556942A patent/JP2024515443A/ja active Pending
- 2022-03-18 WO PCT/US2022/020906 patent/WO2022198020A1/en not_active Ceased
- 2022-03-18 EP EP22772271.7A patent/EP4308923A4/en active Pending
- 2022-03-18 CN CN202280029519.5A patent/CN117178188A/zh active Pending
- 2022-03-18 CA CA3212218A patent/CA3212218A1/en active Pending
- 2022-03-18 KR KR1020237035826A patent/KR20230169172A/ko active Pending
-
2025
- 2025-01-02 US US19/008,245 patent/US20250155448A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4308923A4 (en) | 2025-01-08 |
| EP4308923A1 (en) | 2024-01-24 |
| JP2024515443A (ja) | 2024-04-10 |
| BR112023018869A2 (pt) | 2023-12-05 |
| CN117178188A (zh) | 2023-12-05 |
| WO2022198020A1 (en) | 2022-09-22 |
| US20220299524A1 (en) | 2022-09-22 |
| US12222354B2 (en) | 2025-02-11 |
| CA3212218A1 (en) | 2022-09-22 |
| US20250155448A1 (en) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12493049B2 (en) | Quantitation of insulin-like growth factor-I and insulin-like growth factor-II with high-resolution mass spectrometry | |
| US20250147041A1 (en) | Amyloid beta detection by mass spectrometry | |
| CN103392219B (zh) | 通过质谱法定量胰岛素 | |
| US20250155448A1 (en) | Identification and quantitation of insulin-like growth factor-i variants by mass spectrometry | |
| US20250224404A1 (en) | Detection of insulin-like growth factor-2 variants by mass spectrometry | |
| HK40113272A (en) | Quantitation of insulin-like growth factor-i and insulin-like growth factor-ii with high-resolution mass spectrometry | |
| BR112023018869B1 (pt) | Método para detectar variantes do fator de crescimento tipo insulina-i em uma amostra por espectrometria de massa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231019 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250317 Comment text: Request for Examination of Application |